Lexicon Pharmaceuticals Inc (STU:LX31)
€ 4.096 (0%) Market Cap: 853.40 Mil Enterprise Value: 740.44 Mil PE Ratio: 0 PB Ratio: 5.69 GF Score: 42/100

Lexicon Pharmaceuticals, Inc. at Citi Biopharma Back to School Summit Transcript

Sep 9, 2026 / 03:20 PM GMT
Release Date Price: €4.1


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LXRX.OQ - Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. at Citi Biopharma Back to School Summit
Sep 09, 2026 / 03:20PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Everyone to Citi's Biopharma Back-to-School Summit for 2026.

We're very pleased to be introducing our next company, Lexicon Pharmaceuticals.

We have Mike Exton, CEO. Welcome.

Craig Granowitz, CMO, and Scott Janti, the CFO. Welcome, all of you.

Thank you so much.

I'm Yugan Machamovitz, cover the company for.

Long time.

Well, since before COVID, I think.

Anyway, so maybe, Mike, do you want to just start us off with the quick kind of overview of where things are with sotagliflozin? Of course, you have a very important phase three readout coming up in a critical area of cardiology. So why don't you start with Eric?

-
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot